Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127993711 | 12799371 | 1 | I | 20160927 | 20160930 | 20160930 | EXP | JP-JNJFOC-20160929922 | JANSSEN | MIZUGAKI H, YAMAMOTO N, FUJIWARA Y, NOKIHARA H, YAMADA Y, TAMURA T. CURRENT STATUS OF SINGLE-AGENT PHASE I TRIALS IN JAPAN: TOWARD GLOBALIZATION. JOURNAL OF CLINICAL ONCOLOGY 2015;33 (18):2051-61. | 0.00 | Y | 0.00000 | 20160930 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127993711 | 12799371 | 1 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | U | U | 50718 | 50 | MG/M**2 | LIPOSOME INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127993711 | 12799371 | 1 | Neoplasm |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127993711 | 12799371 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127993711 | 12799371 | Diarrhoea | |
| 127993711 | 12799371 | Hypoxia | |
| 127993711 | 12799371 | Neutropenia | |
| 127993711 | 12799371 | Palmar-plantar erythrodysaesthesia syndrome | |
| 127993711 | 12799371 | Stomatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |